# 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

> **NCT04689828** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 469 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **DRUG:** 68Ga-PSMA-11
- **DRUG:** ARDT

## Key facts

- **NCT ID:** NCT04689828
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-15
- **Primary completion:** 2022-10-02
- **Final completion:** 2026-09-30
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689828, "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04689828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*